An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism:Results from the RZ358-606 (RIZE) StudyWhile
NEJM Letter to the Editor: Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia
Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-Insulin Receptor Antibody
Phase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022
Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism
Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
Rezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editions
Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers
The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial
ENDO 2015 Annual Meeting